Searched for
HABIL KHORAKIWALA
Pharma in her DNA, Wockhardt scion ready for deep dive in the USZahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...- If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil KhorakiwalaWockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected t...
- Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...
- Any tariffs on pharma sector would be counterproductive for Americans: Wockhardt Chairman Habil KhorakiwalaWockhardt Chairman Habil Khorakiwala warns that potential US tariffs on pharmaceutical products would harm Americans. He highlights India's...
- Habil Khorakiwala on 3 things in the pipeline that can cause a re-rating for WockhardtHabil Khorakiwala says: “We have earlier signed an agreement on a profit-sharing basis for contract manufacturing with Serum Institute to m...
- Covid-19 impact: Over 40 nurses test positive in Mumbai hospitalRepresentatives of the nurses who are inside the hospital have alleged that the hospital did not take enough precautions while handling the...
- How Wockhardt Chairman Habil Khorakiwala plans to pull the company out of trouble45 years after he made a profound statement about dying only once, the chairman of Wockhardt would like to repeat it to investors, regulato...
- Buy Wockhardt, target Rs 800: Dr CK NarayanBuy Wockhardt Ltd. at a price target of Rs 800.0 and a stop loss at Rs 775 from entry point.
- Buy Wockhardt, target Rs 825: Kunal BothraBuy Wockhardt at a price target of Rs 825.0 and a stop loss at Rs 725 from entry point.
- Buy Wockhardt, target Rs 770: Dr CK NarayanBuy Wockhardt at a price target of Rs 770 and a stop loss at Rs 745 from entry point.
- Wockhardt chairman Habil Khorakiwala’s double celebration included a 10-course meal, & the crème de la crème of MumbaiKhorakiwala brought in his 75th birthday and his company’s golden jubilee with a lavish party.
- USFDA red-flags lack of controls at Wockhardt's Shendra unit near AurangabadFDA had listed nine observations related to processes followed at the plant, which Wockhardt later clarified were not of a serious nature.
- Strict compliance makes Indian pharma companies stronger: Habil Khorakiwala, Wockhardt"FDA's strict compliance system is a blessing in disguise because on a longer term, it makes the industry much stronger in India to compete...
- How Zahabiya Khorakiwala has made father Habil proudIn particular, there’s one memory that makes both smile: At age 15, Zahabiya was sent to Aiglon boarding school in Switzerland for two year...
- Hard work pays off for Wockhardt: Habil Khorakiwala, Chairman, WockhardtWockhardt has about 70% of its sales accruing from overseas, mostly the US. Hedging is par for the course for companies with forex exposure.
- Not interested in biz: Khorakiwala JrHuzaifa Khorakiwala, the son of Wockhardt promoter Habil Khorakiwala who was recently promoted to the post of wholetime director, says he i...
- Wockhardt plunged over 11 pc on BSEShares of Wockhardt tanked over 11 per cent on the Bombay Stock Exchange, a day after the company said it would undertake a corporate debt ...
- Murtaza’s elevation to top post at Wockhardt strengthens gripWockhardt chairman and managing director Habil Khorakiwala’s move to step down from the post of MD and appoint younger son Murtaza Khorakiw...
- Wockhardt to launch tablets treating infections in USPharmaceutical firm Wockhardt on Tuesday said it will shortly launch Azithromycin tablets, which are used for treating different kinds of i...
- Wockhardt gets US nod for Cefprozil tabsPharma company Wockhardt Ltd on Wednesday said it has received US Food and Drug Administration (USFDA) approval for Cefprozil tablets, an a...
Load More
